Our findings show that BETi along with anti-androgens could be used to mitigate the oncogenic effects of DLX1 via disrupting AR and ERG transcriptional circuitries and can be considered as a potential therapeutic intervention in the treatment of the ERG+/DLX1+ subtype of PCa. This evidence concerns the gene AR and posterior cortical atrophy.